Trial Profile

Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 16 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CD-38-SADA (Primary) ; Radiopharmaceuticals
Indications B-cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
Focus Adverse reactions; First in man
Acronyms Study 1201; Trial 1201
Sponsors Y-mAbs Therapeutics

Most Recent Events

12 Mar 2026 Status changed from recruiting to discontinued.
27 Apr 2025 According to a Y-mAbs Therapeutics media release, dosing has been initiated in this clinical trial.
25 Apr 2025 According to a Y-mAbs Therapeutics media release, first patient has been administered both the first protein dose and the 177Lu-DOTA imaging dose in this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com